• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

    DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).

    For more than two decades, DaVita has invested in care innovation to address the complex, fragmented experience faced by people living with kidney disease. Value-based models enable whole-person, longitudinal care rather than episodic treatment.

    CKCC Results Show Momentum as the Model Matures

    DaVita's progress is reflected in results from the Comprehensive Kidney Care Contracting (CKCC) option within CMMI's Kidney Care Choices model. As the largest ongoing federal value-based kidney care demonstration, CKCC enables providers and physicians to test and refine coordinated care approaches at scale.

    Recently published performance results through 2024 show continued year-over-year improvements as the model matures.

    • Stronger quality outcomes: DaVita achieved a 9% improvement in its Total Quality Score, driven by gains in optimal treatment starts, patient activation and behavioral health support.
    • Greater shared savings: DaVita entities have delivered more than $200 million in shared savings since the program's inception.
    • High Performers recognition: DaVita and its physician partners drove an outsized impact, accounting for 34% of the program's High Performers Pool while representing just 28% of participants.

    Beyond program metrics alone, these improvements are associated with meaningful downstream effects on clinical quality and long-term population health.

    Patients with access to CKCC and related value-based care programs are more likely to:

    • Begin kidney replacement therapy with a planned or optimal start, including increased use of home-based treatment options.
    • Experience lower rates of central venous catheter (CVC) use, supporting safer treatment initiation.
    • Have fewer missed treatments, reflecting stronger engagement and care coordination.

    "People living with kidney disease often manage multiple chronic conditions, and strong outcomes depend on close collaboration across the care team," said Dr. Jeff Giullian, chief medical officer for DaVita. "Through value-based models like CKCC, DaVita works alongside partner physicians and care teams to better coordinate care beyond kidney disease and across settings. That shared approach supports earlier intervention, more prepared treatment starts, and better-informed decisions about dialysis, transplantation and care at home."

    A Significant and Growing Commitment to Value-Based Care

    DaVita has been engaged in value-based care arrangements for more than two decades and now manages more than $5 billion in medical costs under management. Across these models, value-based kidney care is linked to higher transplant rates and greater patient understanding of their condition, enabling more informed, proactive health decisions.

    "Value-based kidney care is showing what's possible when providers are given the time and stability to invest in coordinated care," said Misha Palecek, chief transformation officer for DaVita. "We're seeing better-prepared patients, improved experiences and encouraging economics. The lessons emerging from kidney care can help inform how other complex, chronic conditions are managed across the healthcare system — if we stay the course."

    Supporting Long-Term Innovation in Kidney Care

    DaVita is encouraged that its integrated kidney care programs are demonstrating early signs of financial sustainability alongside improved outcomes. These results reinforce that continued focus on kidney care can drive meaningful gains in healthcare innovation more broadly, with coordinated, accountable care models offering a blueprint for transformation across the healthcare system.

    To learn more about DaVita's approach to value-based kidney care, visit DaVita.com/IKC.

    About DaVita Inc.

    DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey— from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially from these forward-looking statements, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release, except as may be otherwise required by law.

    Media Contact:

    DaVita Newsroom

    newsroom@davita.com

    DaVita Logo (PRNewsfoto/DaVita)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-highlights-continued-progress-in-value-based-kidney-care-as-ckcc-results-show-year-over-year-improvement-302717802.html

    SOURCE DaVita

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    5/6/2026$220.00Hold → Buy
    Deutsche Bank
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    More analyst ratings

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals

    Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities.DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitments, a new set of long-term goals, focused on improving patient outcomes, supporting the expansion of economic opportunity for teammates, and strengthening community and environmental resilience. The announcement follows the company achieving or exceeding the majority of its prior five-year environmental, social, and governance (ESG) goals, reinforcing DaVita's track record of turning ambition into measurable impact.Guided by its Trilogy of Care—Caring for Our Patients, Caring for Each Other and

    5/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 1st Quarter 2026 Results

    DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2026."DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."Financial and operating highlights for the quarter and year ended March 31, 2026:Consolidated revenues were $3.416 billion.Operating income was $482 million.Diluted earnings per share from continuing operations was $2.87.Operating cash flow was $321 million and free cash flow was $140 m

    5/5/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Honeywell Announces Board of Directors for Honeywell Aerospace

    Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgroundsHoneywell spin-off of Honeywell Aerospace expected to be completed on June 29, 2026Management will provide details on Honeywell Aerospace's value creation and financial outlook at an Investor Day on June 3, 2026 CHARLOTTE, N.C., April 28, 2026 /PRNewswire/ -- Honeywell (NASDAQ:HON) today announced the anticipated Board of Directors for Honeywell Aerospace, which will be one of the largest publicly listed pure-play aerospace and defense companies following its planned spin-off from Honeywell.

    4/28/26 7:00:00 AM ET
    $DVA
    $HON
    Misc Health and Biotechnology Services
    Health Care
    Aerospace
    Industrials

    $DVA
    SEC Filings

    View All

    SEC Form 144 filed by DaVita Inc.

    144 - DAVITA INC. (0000927066) (Subject)

    5/6/26 4:03:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by DaVita Inc.

    10-Q - DAVITA INC. (0000927066) (Filer)

    5/5/26 5:03:02 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    5/5/26 4:09:12 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DaVita upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded DaVita from Hold to Buy and set a new price target of $220.00

    5/6/26 7:31:43 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/28/26 4:22:54 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/18/26 4:11:56 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/18/26 4:11:45 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 1st Quarter 2026 Results

    DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2026."DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."Financial and operating highlights for the quarter and year ended March 31, 2026:Consolidated revenues were $3.416 billion.Operating income was $482 million.Diluted earnings per share from continuing operations was $2.87.Operating cash flow was $321 million and free cash flow was $140 m

    5/5/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care